The consumer watchdog group, Public Citizen, this week asked the U.S. Food and Drug Administration not to approve the drug, rivaroxaban (Xarelto), for use in patients with atrial fibrillation, citing concerns over the drug’s overall safety and efficacy. The group issued a letter to the FDA, specifically addressing a recent discrepancy in opinion between an [...]
